J Korean Med Sci.  2011 Nov;26(11):1515-1517. 10.3346/jkms.2011.26.11.1515.

Dura Mater Graft-Associated Creutzfeldt-Jakob Disease: The First Case in Korea

• Kim HL
• Do JY
• Cho HJ
• Jeon YC
• Park SJ
• Ma HI
• Song JH
• Lee Y
• Choi H
• Choi KC
• Kim YS
• Zerr I
• Kallenberg K
• Kim YJ

• KMID: 1123455
• DOI: http://doi.org/10.3346/jkms.2011.26.11.1515

Abstract

Since 1987, dura mater graft-associated iatrogenic Creutzfeldt-Jakob disease (dCJD) has been reported in many countries. We report the first case of dCJD in Korea. A 54-yr-old woman, who underwent resection of the meningioma in the left frontal region and received a dura mater graft 23 yr ago presented with dysesthesia followed by psychiatric symptoms and ataxia. Her neurological symptoms rapidly progressed to such an extent that she exhibited myoclonus, dementia, and pyramidal and extrapyramidal signs within 8 weeks. The 14-3-3 protein was detected in her cerebrospinal fluid; however, an electroencephalogram did not reveal characteristic positive sharp wave complexes. Diffusion-weighted magnetic resonance images, obtained serially over 64 days, revealed the rapid progression of areas of high signal intensity in the caudate nucleus and cingulate gyrus to widespread areas of high signal intensity in the cortex and basal ganglia. Pathological examination of brain biopsy specimens confirmed the presence of spongiform changes and deposition of prion protein in the neurons and neuropils.

Keyword

Creutzfeldt-Jakob Syndrome; Dura Mater Graft; Iatrogenic Disease

MeSH Terms

14-3-3 Proteins/cerebrospinal fluid
Ataxia/diagnosis
Brain/pathology
Creutzfeldt-Jakob Syndrome/diagnosis/pathology/*transmission
Dementia/diagnosis
Dura Mater/*transplantation
Female
Humans
Meningioma/surgery
Middle Aged
Paresthesia/diagnosis
Prions/*analysis
Republic of Korea
Transplants

Figure

• 

  Fig. 1 Serial DWIs taken during the course of dCJD. The first DWI (left column), taken almost 6 weeks after her first neurological symptoms, revealedslightly increased signal intensity in the cingulate gyrus and the caudate nucleus. In the second DWI (middle column), taken 10 weeks after her first neurological symptoms, high signal intensity in both insulae, the caudate nucleus, and the medial frontal cortical region became obvious. In the third DWI (right column), taken 12 weeks after her first neurological symptoms, extensive high signal intensity was observed in the both basal ganglia and the cortex.

• 

  Fig. 2 Microscopic findings. (A) Neuronal loss and spongiform change (hematoxylin and eosin stain). (B) Astrocytosis detected using an anti-GFAP antibody. (C) Deposition of prion protein monoclonal antibody (1C5) for prion protein (arrow).

Reference

1. Brown P, Brandel JP, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology. 2006. 67:389–393.

2. Thadani V, Penar PL, Partington J, Kalb R, Janssen R, Schonberger LB, Rabkin CS, Prichard JW. Creutzfeldt-Jakob disease probably acquired from a cadaveric dura mater graft. Case report. J Neurosurg. 1988. 69:766–769.

3. Tintner R, Brown P, Hedley-Whyte ET, Rappaport EB, Piccardo CP, Gajdusek DC. Neuropathologic verification of Creutzfeldt-Jakob disease in the exhumed American recipient of human pituitary growth hormone: epidemiologic and pathogenetic implications. Neurology. 1986. 36:932–936.

4. Hogan RN, Cavanagh HD. Transplantation of corneal tissue from donors with diseases of the central nervous system. Cornea. 1995. 14:547–553.

5. Simpson DA, Masters CL, Ohlrich G, Purdie G, Stuart G, Tannenberg AE. Iatrogenic Creutzfeldt-Jakob disease and its neurosurgical implications. J Clin Neurosci. 1996. 3:118–123.

6. Bryce EA, Dorovoni-Zis K, Trudeau D, Sinclair M, Roberts FJ. Creutzfeldt-Jakob disease: management of accidental contamination of neurosurgical instruments, pathology equipment, and solutions. Infect Control Hosp Epidemiol. 2000. 21:247–248.

7. Heath CA, Barker RA, Esmonde TF, Harvey P, Roberts R, Trend P, Head MW, Smith C, Bell JE, Ironside JW, Will RG, Knight RS. Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK. J Neurol Neurosurg Psychiatry. 2006. 77:880–882.

8. Brooke FJ, Boyd A, Klug GM, Masters CL, Collins SJ. Lyodura use and the risk of iatrogenic Creutzfeldt-Jakob disease in Australia. Med J Aust. 2004. 180:177–181.

9. Noguchi-Shinohara M, Hamaguchi T, Kitamoto T, Sato T, Nakamura Y, Mizusawa H, Yamada M. Clinical features and diagnosis of dura mater graft associated Creutzfeldt Jakob disease. Neurology. 2007. 69:360–367.

10. Yamada M, Noguchi-Shinohara M, Hamaguchi T, Nozaki I, Kitamoto T, Sato T, Nakamura Y, Mizusawa H. Dura mater graft-associated Creutzfeldt-Jakob disease in Japan: clinicopathological and molecular characterization of the two distinct subtypes. Neuropathology. 2009. 29:609–618.

11. Meissner B, Kallenberg K, Sanchez-Juan P, Ramljak S, Krasnianski A, Heinemann U, Eigenbrod S, Gelpi E, Barsic B, Kretzschmar HA, Schulz-Schaeffer WJ, Knauth M, Zerr I. MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease. J Neurol. 2009. 256:355–363.

12. Yamada M, Nozaki I, Hamaguchi T, Noguchi-Shinohara M, Kitamoto T, Nakamura Y, Sato T, Mizusawa H. Prion disease surveillance in Japan: analysis of 1,241 patients. Rinsho Shinkeigaku. 2009. 49:939–942.

13. Centers for Disease Control and Prevention (CDC). Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts: Japan, 1979-2003. MMWR Morb Mortal Wkly Rep. 2003. 52:1179–1181.

14. Nakamura Y, Yanagawa H, Hoshi K, Yoshino H, Urata J, Sato T. Incidence rate of Creutzfeldt-Jakob disease in Japan. Int J Epidemiol. 1999. 28:130–134.